company background image
PKTX logo

ProtoKinetix OTCPK:PKTX Stock Report

Last Price

US$0.011

Market Cap

US$3.9m

7D

5.0%

1Y

-36.4%

Updated

04 Nov, 2024

Data

Company Financials

ProtoKinetix, Incorporated

OTCPK:PKTX Stock Report

Market Cap: US$3.9m

PKTX Stock Overview

A research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).

PKTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ProtoKinetix, Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ProtoKinetix
Historical stock prices
Current Share PriceUS$0.011
52 Week HighUS$0.029
52 Week LowUS$0.008
Beta-0.034
11 Month Change-15.87%
3 Month Change-26.06%
1 Year Change-36.36%
33 Year Change-88.83%
5 Year Change-90.28%
Change since IPO162.50%

Recent News & Updates

Recent updates

Shareholder Returns

PKTXUS BiotechsUS Market
7D5.0%-0.7%-1.6%
1Y-36.4%19.8%30.8%

Return vs Industry: PKTX underperformed the US Biotechs industry which returned 19.8% over the past year.

Return vs Market: PKTX underperformed the US Market which returned 30.8% over the past year.

Price Volatility

Is PKTX's price volatile compared to industry and market?
PKTX volatility
PKTX Average Weekly Movement36.2%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: PKTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PKTX's weekly volatility (36%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999n/aClarence Smithwww.protokinetix.com

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company’s AFGPs have commercial applications primarily in health care solutions, including ophthalmology, dermatology, transplants, and biomanufacturing. It has a collaboration research agreement with the University of British Columbia.

ProtoKinetix, Incorporated Fundamentals Summary

How do ProtoKinetix's earnings and revenue compare to its market cap?
PKTX fundamental statistics
Market capUS$3.85m
Earnings (TTM)-US$369.97k
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PKTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$369.97k
Earnings-US$369.97k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.001
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PKTX perform over the long term?

See historical performance and comparison